collection
MENU ▼
Read by QxMD icon Read
search

Cost-effectiveness research

shared collection
430 papers 25 to 100 followers Cost-effectiveness, cost-utility, value of information, willingness to pay, technology assessment, economic evaluation
By Jamie Jarmul Md / PhD student at UNC - Chapel Hill, PhD in Health Policy and Management
https://www.readbyqxmd.com/read/29485322/colorectal-cancer-cost-effectiveness-of-colonoscopy-versus-ct-colonography-screening-with-participation-rates-and-costs
#1
RANDOMIZED CONTROLLED TRIAL
Miriam P van der Meulen, Iris Lansdorp-Vogelaar, S Lucas Goede, Ernst J Kuipers, Evelien Dekker, Jaap Stoker, Marjolein van Ballegooijen
Purpose To compare the cost-effectiveness of computed tomographic (CT) colonography and colonoscopy screening by using data on unit costs and participation rates from a randomized controlled screening trial in a dedicated screening setting. Materials and Methods Observed participation rates and screening costs from the Colonoscopy or Colonography for Screening, or COCOS, trial were used in a microsimulation model to estimate costs and quality-adjusted life-years (QALYs) gained with colonoscopy and CT colonography screening...
June 2018: Radiology
https://www.readbyqxmd.com/read/29477389/an-overview-of-value-perspective-and-decision-context-a-health-economics-approach-an-ispor-special-task-force-report-2
#2
Louis P Garrison, Mark V Pauly, Richard J Willke, Peter J Neumann
The second section of our Special Task Force builds on the discussion of value and perspective in the previous article of the report by 1) defining a health economics approach to the concept of value in health care systems; 2) discussing the relationship of value to perspective and decision context, that is, how recently proposed value frameworks vary by the types of decisions being made and by the stakeholders involved; 3) describing the patient perspective on value because the patient is a key stakeholder, but one also wearing the hat of a health insurance purchaser; and 4) discussing how value is relevant in the market-based US system of mixed private and public insurance, and differs from its use in single-payer systems...
February 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/29477390/defining-elements-of-value-in-health-care-a-health-economics-approach-an-ispor-special-task-force-report-3
#3
Darius N Lakdawalla, Jalpa A Doshi, Louis P Garrison, Charles E Phelps, Anirban Basu, Patricia M Danzon
The third section of our Special Task Force report identifies and defines a series of elements that warrant consideration in value assessments of medical technologies. We aim to broaden the view of what constitutes value in health care and to spur new research on incorporating additional elements of value into cost-effectiveness analysis (CEA). Twelve potential elements of value are considered. Four of them-quality-adjusted life-years, net costs, productivity, and adherence-improving factors-are conventionally included or considered in value assessments...
February 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/29477391/objectives-budgets-thresholds-and-opportunity-costs-a-health-economics-approach-an-ispor-special-task-force-report-4
#4
Patricia M Danzon, Michael F Drummond, Adrian Towse, Mark V Pauly
The fourth section of our Special Task Force report focuses on a health plan or payer's technology adoption or reimbursement decision, given the array of technologies, on the basis of their different values and costs. We discuss the role of budgets, thresholds, opportunity costs, and affordability in making decisions. First, we discuss the use of budgets and thresholds in private and public health plans, their interdependence, and connection to opportunity cost. Essentially, each payer should adopt a decision rule about what is good value for money given their budget; consistent use of a cost-per-quality-adjusted life-year threshold will ensure the maximum health gain for the budget...
February 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/29477392/approaches-to-aggregation-and-decision-making-a-health-economics-approach-an-ispor-special-task-force-report-5
#5
Charles E Phelps, Darius N Lakdawalla, Anirban Basu, Michael F Drummond, Adrian Towse, Patricia M Danzon
The fifth section of our Special Task Force report identifies and discusses two aggregation issues: 1) aggregation of cost and benefit information across individuals to a population level for benefit plan decision making and 2) combining multiple elements of value into a single value metric for individuals. First, we argue that additional elements could be included in measures of value, but such elements have not generally been included in measures of quality-adjusted life-years. For example, we describe a recently developed extended cost-effectiveness analysis (ECEA) that provides a good example of how to use a broader concept of utility...
February 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/29477393/review-of-recent-us-value-frameworks-a-health-economics-approach-an-ispor-special-task-force-report-6
#6
Richard J Willke, Peter J Neumann, Louis P Garrison, Scott D Ramsey
The sixth section of our Special Task Force (STF) report reviews and comments on recent US-oriented value assessment frameworks, specifically those published by the American College of Cardiology/American Heart Association, the Institute for Clinical and Economic Research, the American Society of Clinical Oncology, the National Comprehensive Cancer Network, and the Memorial Sloan Kettering Cancer Center. We review published commentaries that address the validity, reliability, and conceptual underpinnings of these frameworks...
February 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/29477394/a-health-economics-approach-to-us-value-assessment-frameworks-summary-and-recommendations-of-the-ispor-special-task-force-report-7
#7
Louis P Garrison, Peter J Neumann, Richard J Willke, Anirban Basu, Patricia M Danzon, Jalpa A Doshi, Michael F Drummond, Darius N Lakdawalla, Mark V Pauly, Charles E Phelps, Scott D Ramsey, Adrian Towse, Milton C Weinstein
This summary section first lists key points from each of the six sections of the report, followed by six key recommendations. The Special Task Force chose to take a health economics approach to the question of whether a health plan should cover and reimburse a specific technology, beginning with the view that the conventional cost-per-quality-adjusted life-year metric has both strengths as a starting point and recognized limitations. This report calls for the development of a more comprehensive economic evaluation that could include novel elements of value (e...
February 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/29477395/ispor-s-initiative-on-us-value-assessment-frameworks-the-use-of-cost-effectiveness-research-in-decision-making-among-us-insurers
#8
Brian Solow, Edmund J Pezalla
No abstract text is available yet for this article.
February 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/29477400/a-comparison-of-different-approaches-for-costing-medication-use-in-an-economic-evaluation
#9
COMPARATIVE STUDY
Margaret Heslin, Oluwagbemisola Babalola, Fowzia Ibrahim, Dominic Stringer, David Scott, Anita Patel
BACKGROUND: Estimating individual-level medication costs in an economic evaluation can involve extensive data collection and handling. Implications of detailed versus general approaches are unclear. OBJECTIVES: To compare costing approaches in a trial-based economic evaluation. METHODS: We applied four costing approaches to prescribed medication data from the Tumour necrosis factor inhibitors Against Combination Intensive Therapy randomized controlled trial...
February 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/29477402/the-impact-of-decision-makers-constraints-on-the-outcome-of-value-of-information-analysis
#10
Hendrik Koffijberg, Saskia Knies, Mart P Janssen
BACKGROUND: When proven effective, decision making regarding reimbursement of new health technology typically involves ethical, social, legal, and health economic aspects and constraints. Nevertheless, when applying standard value of information (VOI) analysis, the value of collecting additional evidence is typically estimated assuming that only cost-effectiveness outcomes guide such decisions. OBJECTIVES: To illustrate how decision makers' constraints can be incorporated into VOI analyses and how these may influence VOI outcomes...
February 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/29477406/examining-the-heterogeneity-and-cost-effectiveness-of-a-complex-intervention-by-segmentation-of-patients-with-chronic-obstructive-pulmonary-disease
#11
Sabrina Storgaard Sørensen, Morten Berg Jensen, Kjeld Møller Pedersen, Lars Ehlers
OBJECTIVES: To examine the heterogeneity in cost-effectiveness analyses of patient-tailored complex interventions. METHODS: Latent class analysis (LCA) was performed on data from a randomized controlled trial evaluating a patient-tailored case management strategy for patients suffering from chronic obstructive pulmonary disease (COPD). LCA was conducted on detailed process variables representing service variation in the intervention group. Features of the identified latent classes were compared for consistency with baseline demographic, clinical, and economic characteristics for each class...
February 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/29481917/cost-effectiveness-of-generic-celecoxib-in-knee-osteoarthritis-for-average-risk-patients-a-model-based-evaluation
#12
E Losina, I M Usiskin, S R Smith, J K Sullivan, K C Smith, D J Hunter, S P Messier, A D Paltiel, J N Katz
OBJECTIVE: The cost-effectiveness of the recently-introduced generic celecoxib in knee OA has not been examined. METHOD: We used the Osteoarthritis Policy (OAPol) Model, a validated computer simulation of knee OA, to evaluate long-term clinical outcomes, costs, and cost-effectiveness of generic celecoxib in persons with knee OA. We examined eight treatment strategies consisting of generic celecoxib, over-the-counter (OTC) naproxen, or prescription naproxen, with or without prescription or OTC proton-pump-inhibitors (PPIs) to reduce gastrointestinal (GI) toxicity...
May 2018: Osteoarthritis and Cartilage
https://www.readbyqxmd.com/read/29471877/a-personalized-intervention-to-prevent-depression-in-primary-care-cost-effectiveness-study-nested-into-a-clustered-randomized-trial
#13
RANDOMIZED CONTROLLED TRIAL
Anna Fernández, Juan M Mendive, Sonia Conejo-Cerón, Patricia Moreno-Peral, Michael King, Irwin Nazareth, Carlos Martín-Pérez, Carmen Fernández-Alonso, Antonina Rodríguez-Bayón, Jose Maria Aiarzaguena, Carmen Montón-Franco, Antoni Serrano-Blanco, Inmaculada Ibañez-Casas, Emiliano Rodríguez-Sánchez, Luis Salvador-Carulla, Paola Bully Garay, María Isabel Ballesta-Rodríguez, Pilar LaFuente, María Del Mar Muñoz-García, Pilar Mínguez-Gonzalo, Luz Araujo, Diego Palao, María Cruz Gómez, Fernando Zubiaga, Desirée Navas-Campaña, Jose Manuel Aranda-Regules, Alberto Rodriguez-Morejón, Juan de Dios Luna, Juan Ángel Bellón
BACKGROUND: Depression is viewed as a major and increasing public health issue, as it causes high distress in the people experiencing it and considerable financial costs to society. Efforts are being made to reduce this burden by preventing depression. A critical component of this strategy is the ability to assess the individual level and profile of risk for the development of major depression. This paper presents the cost-effectiveness of a personalized intervention based on the risk of developing depression carried out in primary care, compared with usual care...
February 23, 2018: BMC Medicine
https://www.readbyqxmd.com/read/29468944/estimating-cost-effectiveness-from-claims-and-registry-data-with-measured-and-unmeasured-confounders
#14
Elizabeth A Handorf, Daniel F Heitjan, Justin E Bekelman, Nandita Mitra
The analysis of observational data to determine the cost-effectiveness of medical treatments is complicated by the need to account for skewness, censoring, and the effects of measured and unmeasured confounders. We quantify cost-effectiveness as the Net Monetary Benefit (NMB), a linear combination of the treatment effects on cost and effectiveness that denominates utility in monetary terms. We propose a parametric estimation approach that describes cost with a Gamma generalized linear model and survival time (the canonical effectiveness variable) with a Weibull accelerated failure time model...
January 1, 2018: Statistical Methods in Medical Research
https://www.readbyqxmd.com/read/29470854/the-cost-effectiveness-of-screening-in-the-community-to-reduce-osteoporotic-fractures-in-older-women-in-the-uk-economic-evaluation-of-the-scoop-study
#15
David A Turner, Rebekah Fong Soe Khioe, Lee Shepstone, Elizabeth Lenaghan, Cyrus Cooper, Neil Gittoes, Nicholas C Harvey, Richard Holland, Amanda Howe, Eugene McCloskey, Terence W O'Neill, David Torgerson, Richard Fordham
The SCOOP study was a two-arm randomized controlled trial conducted in the UK in 12,483 eligible women aged 70 to 85 years. It compared a screening program using the FRAX® risk assessment tool in addition to bone mineral density (BMD) measures versus usual management. The SCOOP study found a reduction in the incidence of hip fractures in the screening arm, but there was no evidence of a reduction in the incidence of all osteoporosis-related fractures. To make decisions about whether to implement any screening program, we should also consider whether the program is likely to be a good use of health care resources, ie, is it cost-effective? The cost per gained quality adjusted life year of screening for fracture risk has not previously been demonstrated in an economic evaluation alongside a clinical trial...
May 2018: Journal of Bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research
https://www.readbyqxmd.com/read/29406347/the-cost-effectiveness-of-surgical-fixation-of-distal-radial-fractures-a-computer-model-based-evaluation-of-three-operative-modalities
#16
Prashant V Rajan, Rameez A Qudsi, George S M Dyer, Elena Losina
BACKGROUND: There is no consensus on the optimal fixation method for patients who require a surgical procedure for distal radial fractures. We used cost-effectiveness analyses to determine which of 3 modalities offers the best value: closed reduction and percutaneous pinning, open reduction and internal fixation, or external fixation. METHODS: We developed a Markov model that projected short-term and long-term health benefits and costs in patients undergoing a surgical procedure for a distal radial fracture...
February 7, 2018: Journal of Bone and Joint Surgery. American Volume
https://www.readbyqxmd.com/read/29420742/population-level-outcomes-and-cost-effectiveness-of-expanding-the-recommendation-for-age-based-hepatitis-c-testing-in-the-united-states
#17
Joshua A Barocas, Abriana Tasillo, Golnaz Eftekhari Yazdi, Jianing Wang, Claudia Vellozzi, Susan Hariri, Cheryl Isenhour, Liisa Randall, John W Ward, Jonathan Mermin, Joshua A Salomon, Benjamin P Linas
Background: The U.S. Centers for Disease Control and Prevention and the U.S. Preventive Services Task Force recommend one-time hepatitis C virus (HCV) testing for persons born 1945-1965 and targeted testing for high-risk persons. This strategy targets HCV testing to a prevalent population at high risk for HCV morbidity and mortality, but does not include younger populations with high incidence. To address this gap and improve access to HCV testing, age-based strategies should be considered...
February 6, 2018: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/29421472/health-care-input-constraints-and-cost-effectiveness-analysis-decision-rules
#18
Pieter van Baal, Alec Morton, Johan L Severens
Results of cost effectiveness analyses (CEA) studies are most useful for decision makers if they face only one constraint: the health care budget. However, in practice, decision makers wishing to use the results of CEA studies may face multiple resource constraints relating to, for instance, constraints in health care inputs such as a shortage of skilled labour. The presence of multiple resource constraints influences the decision rules of CEA and limits the usefulness of traditional CEA studies for decision makers...
March 2018: Social Science & Medicine
https://www.readbyqxmd.com/read/29304936/cost-effectiveness-and-value-of-information-analysis-of-brief-interventions-to-promote-physical-activity-in-primary-care
#19
Vijay Singh Gc, Marc Suhrcke, Wendy Hardeman, Stephen Sutton, Edward C F Wilson
BACKGROUND: Brief interventions (BIs) delivered in primary care have shown potential to increase physical activity levels and may be cost-effective, at least in the short-term, when compared with usual care. Nevertheless, there is limited evidence on their longer term costs and health benefits. OBJECTIVES: To estimate the cost-effectiveness of BIs to promote physical activity in primary care and to guide future research priorities using value of information analysis...
January 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/29052163/the-use-of-health-state-utility-values-in-decision-models
#20
REVIEW
Roberta Ara, John Brazier, Ismail Azzabi Zouraq
Methodological issues of how to use health state utility values (HSUVs) in decision models arise frequently, including the most appropriate evidence to use as the baseline (e.g. the baseline HSUVs associated with avoiding a particular health condition or event), how to capture changes due to adverse events and how to appropriately capture uncertainty in progressive conditions where the expected change in quality of life is likely to be monotonically decreasing over time. As preference-based measures provide different values when collected from the same patient, it is important to ensure that all HSUVs used within a single model are obtained from the same instrument where ever possible...
December 2017: PharmacoEconomics
label_collection
label_collection
3654
1
2
2018-01-06 01:24:55
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"